Bill Pullman

Q: What Schools Are Affiliated With Bill Pullman

Bill Pullman is affiliated with the following schools: Montana State University, State University of New York at Delhi, University of Massachusetts Amherst, State University of New York at Oneonta

Why Is Bill Pullman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William Pullman is an American actor. After graduating with a Master of Fine Arts degree in theater, he was an adjunct professor at Montana State University before deciding to pursue acting. He made his film debut in Ruthless People , and starred in Spaceballs , The Accidental Tourist , Sleepless in Seattle , While You Were Sleeping , Casper , Independence Day , Lost Highway , and Lake Placid . He has appeared frequently on television, usually in TV films. Starting in the 2000s he has also acted in miniseries and regular series, such as Torchwood , starring roles in 1600 Penn and The Sinner . In 2021, he had a recurring role in the miniseries Halston.

(See a Problem?)

Bill Pullman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ecallantide for the treatment of acute attacks in hereditary angioedema. (2010) (166)
Enhanced mucosal cytokine production in inflammatory bowel disease. (1992) (154)
EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. (2010) (132)
Economic costs associated with acute attacks and long-term management of hereditary angioedema. (2010) (131)
Cloning and characterization of a gene that regulates cell adhesion (1992) (99)
Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. (1988) (65)
From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference (2004) (61)
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. (2011) (58)
Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. (2004) (44)
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open‐label extension trial (2019) (28)
Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. (2013) (25)
Response time for ecallantide treatment of acute hereditary angioedema attacks. (2010) (23)
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. (2013) (22)
Technetium-99m autologous phagocyte scanning: a new imaging technique for inflammatory bowel disease. (1986) (20)
Lysis of colonic epithelial cells by allogeneic mononuclear and lymphokine activated killer cells derived from peripheral blood and intestinal mucosa: evidence against a pathogenic role in inflammatory bowel disease. (1988) (18)
The role of myonuclei in muscle regeneration: An in vitro study (1978) (17)
Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. (2012) (15)
Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema (2012) (9)
Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double‐blind, randomized, placebo‐controlled trial (2020) (6)
Hypersensitivity Reactions Following Ecallantide Treatment for Acute Attacks of HAE (2010) (6)
Rapid assay and identification of human haemopoietic growth factors. (1989) (5)
Daily and on-demand IC351 treatment of erectile dysfunction (2000) (4)
Cloning and characterization of a gene that regulates cell adhesion. (1992) (3)
Ecallantide Treatment for Acute Attacks of HAE by Primary Attack Location (2010) (2)
Analysis of leucocyte functions in inflammatory bowel disease (1988) (2)
Hypersensitivity Reactions to Ecallantide: an Update of the Clinical Trial Experience and Post-Market Surveillance for Treatment of Attacks of Hereditary Angioedema (2012) (1)
Interim Results from Continuation-the Ongoing, Open-Label, Extension Study of Ecallantide for the Treatment of Acute Attacks of Hereditary Angioedema (2010) (1)
Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial (2022) (1)
Erratum: Cloning and characterization (Nature (1992) 356 (529-532)) (1993) (1)
Oral dosage form to treat sexual dysfunction. (2000) (0)
Technetium-99m autologous phagocyte scanning for inflammatory bowel disease (1986) (0)
Rates of Rebound or Relapse Among Acute Attacks of Hereditary Angioedema Treated with Ecallantide in Open-Label, Repeat-Treatment Study (2012) (0)
Article manufacture for human pharmaceutical use (2000) (0)
Subcutaneous Ecallantide for the Treatment of Acute Attacks of Hereditary Angioedema: The Integrated Analysis of EDEMA3-DB and EDEMA4 (2010) (0)
On-demand treatment of erectile dysfunction with IC351 (2000) (0)
Articles of manufacture with phosphodiesterase inhibitor (2000) (0)
Ecallantide Reverses Laryngeal Hereditary Angioedema Attacks: Experience from the EDEMA Clinical Development Program (2012) (0)
Efficacy and Safety of Ecallantide Treatment for HAE Attacks in Patients Treated with Both Ecallantide and Placebo (2012) (0)
COMPOSITION COMPREHENSIVE INHIBITORS FOR PHOSPHODIESTERASE TO treating sexual dysfunction (2000) (0)
Time to response outcomes in hereditary angioedema. (2011) (0)
Composition for the treatment of sexual the phosphodiesterase-5 inhibitors including funktionsstoerungen (2000) (0)
Differential cytokine production by natural killer cells and T cells of the alpha beta and gamma delta T-cell receptor classes. (1989) (0)
Compositions containing phosphodiesterase inhibitors for the treatment of sexual dysfunction. (2000) (0)
Efficacy of Ecallantide for Acute HAE Attacks Is Maintained Across Multiple Treatments: Results from the EDEMA Development Program (2010) (0)
Manufactured article for human pharmaceutical use (2000) (0)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects (2022) (0)
Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the Masp-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) (2022) (0)

This paper list is powered by the following services:

Other Resources About Bill Pullman

What Schools Are Affiliated With Bill Pullman?

Bill Pullman is affiliated with the following schools:

Why Is Bill Pullman Influential?

Bill Pullman's Published Works

Published Works

Other Resources About Bill Pullman

What Schools Are Affiliated With Bill Pullman?

Image Attributions